G. Romieu

发表

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

P. Neven, V. Semiglazov, S. Johnston, 2008, Breast Cancer Research and Treatment.

Landscape of somatic mutations in 560 breast cancer whole genome sequences

David C. Jones, E. Birney, M. Ringnér, 2016, Nature.

Pan-cancer analysis of whole genomes

Steven J. M. Jones, Nuno A. Fonseca, Icgc, 2020, Nature.

Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?

Franck Bonnetain, Maryse Fiche, William Jacot, 2014, Critical reviews in oncology/hematology.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Saeed Sadeghi, Allison Florance, H. Gómez, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial

G. Romieu, O. Trédan, V. D’Hondt, 2020, Nutrients.

Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines.

S. Culine, F. Pinguet, F. Bressolle, 1999, International journal of oncology.

A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC).

H. Wildiers, J. Jassem, L. Dirix, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer.

P. Colombo, G. Romieu, P. Lamy, 2014, Future oncology.

Letrozole sensitizes breast cancer cells to ionizing radiation

P. Martineau, G. Romieu, P. Pujol, 2004, Breast Cancer Research.

Adjuvant early breast cancer systemic therapies according to daily used technologies.

G. Romieu, W. Jacot, D. Azria, 2012, Critical reviews in oncology/hematology.

Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study

G. Romieu, W. Jacot, M. Fabbro, 2010, Breast Cancer.

Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support.

W. Brugger, G. Romieu, P. Bacon, 2009, Critical reviews in oncology/hematology.

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

F. Bertucci, J. Lemonnier, J. Bonneterre, 2016, The Lancet. Oncology.

Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06

G. Romieu, X. Pivot, M. Demarchi, 2013, Targeted Oncology.

Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2− pN0 early breast cancers

P. Colombo, G. Romieu, P. Lamy, 2017, Breast Cancer Research and Treatment.

Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.

M. Campone, G. Romieu, F. Bidard, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

D. Miles, L. Dirix, G. Romieu, 2013, British Journal of Cancer.

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.

V. Valero, M. Tubiana-Hulin, G. Romieu, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

F. Puglisi, G. Romieu, G. von Minckwitz, 2014, The Lancet. Oncology.

Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study

G. Romieu, W. Jacot, S. Thézénas, 2010, BMC Cancer.

Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.

W. Brugger, G. Romieu, P. Fargeot, 2007, Critical reviews in oncology/hematology.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

R. Greil, F. André, V. Semiglazov, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

M. Parmar, J. Mackey, D. Cameron, 2013, The Lancet. Oncology.

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

H. Wildiers, J. Jassem, L. Dirix, 2015, Breast.

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.

P. Fasching, R. Greil, R. Kreienberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

D. Campos, G. Romieu, P. Reichardt, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR).

M. Campone, G. Romieu, J. Pierga, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of alternating combination chemotherapy in small cell lung cancer

P. Demoly, G. Romieu, J. Pujol, 1991 .

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

J. S. Kim, M. Espié, Sung-Bae Kim, 2021, Breast Cancer Research and Treatment.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

F. Bertucci, F. André, J. Lemonnier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.

A. Schneeweiss, R. Kreienberg, J. Mayordomo, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Dose‐Finding Study of Zoledronate in Hypercalcemic Cancer Patients

G. Romieu, J. Body, A. Lortholary, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer

C. Friedenreich, D. Cox, F. Penault-Llorca, 2020, Scientific Reports.

Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.

F. André, J. Lemonnier, J. Bonneterre, 2015 .

Abstract P2-02-17: T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial

M. Espié, M. Bollet, G. Romieu, 2016 .

Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.

L. Mauriac, J. Canon, G. Romieu, 2009 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Summary version of the standards, options and recommendations for nonmetastatic breast cancer (updated January 2001)

R. Gilles, M. Dilhuydy, L. Mauriac, 2003, British Journal of Cancer.

The antiprogestin RU486 in advanced breast cancer: Preliminary clinical trial

G. Romieu, T. Maudelonde, A. Ulmann, 1988 .

The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial.

G. Romieu, T. Maudelonde, H. Rochefort, 1986, Bulletin du cancer.

Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial.

G. Romieu, M. Ozsahin, N. Crompton, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Arlene Chan, Andreas Schneeweiss, Luc Y Dirix, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).

K. Kern, G. Romieu, J. Crown, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study

A. Schneeweiss, T. Delozier, A. Lluch, 2005 .

Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.

G. Romieu, W. Jacot, J. Ferrero, 2013, Breast.

Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study.

G. Romieu, P. Lamy, V. D’Hondt, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P6-12-03: Meta-Analysis of Patients with Triple-Negative Breast Cancer (TNBC) from Three Randomized Trials of First-Line Bevacizumab (BV) and Chemotherapy Treatment for Metastatic Breast Cancer (MBC)

D. Miles, G. Romieu, J. O’Shaughnessy, 2010 .

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers

G. Romieu, E. Crapez, P. Lamy, 2018, British Journal of Cancer.

A French prospective pilot study for identifying dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients (pts) receiving capecitabine (cap)

F. Pinguet, J. Bonneterre, G. Romieu, 2013 .

Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.

T. Delozier, M. Campone, T. Petit, 2009 .

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

R. Greil, F. André, V. Semiglazov, 2011 .

Impact of symptoms and toxicity on quality of life: Exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer.

A. Schneeweiss, S. Chan, G. Romieu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.

G. Romieu, W. Jacot, B. Guillot, 2012 .

Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.

G. Romieu, W. Jacot, B. Guillot, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer

A. Callegaro, G. Curigliano, M. Campone, 2016, Breast Cancer Research and Treatment.

Patterns of somatic structural variation in human cancer genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature.

PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy

G. Romieu, P. Lamy, F. Dalenc, 2019, Breast Cancer Research and Treatment.

Serum NSE, MMP‐9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?

Amélie Darlix, William Jacot, G. Romieu, 2016, International journal of cancer.

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

C. Lefebvre, F. André, M. Lacroix-Triki, 2016, PLoS medicine.

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature Communications.

Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy.

S. Culine, M. Ychou, G. Romieu, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences

E. Birney, M. Ringnér, A. Børresen-Dale, 2019, Nature.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Alain Viari, Thomas Bachelot, Michael R. Stratton, 2016, Nature Communications.

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

M. Campone, G. Romieu, J. Pierga, 2013, The Lancet. Oncology.

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles

G. Romieu, P. Lamy, F. Bibeau, 2011, Breast Cancer Research.

Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site.

S. Culine, F. Pinguet, M. Ychou, 2003, Anticancer research.

5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site.

S. Culine, M. Ychou, G. Romieu, 2001, Anticancer research.

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer

G. Romieu, P. Lamy, F. Bibeau, 2013, BMC Cancer.

Phase II Trial of Dose Dense Docetaxel Followed by FEC100 as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer

P. Colombo, G. Romieu, F. Bibeau, 2010, American journal of clinical oncology.

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

J. Machiels, F. Penault-Llorca, B. Asselain, 2012, The oncologist.

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

N. Harbeck, D. Miles, L. Dirix, 2008 .

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

H. Blanché, M. Mathieu, H. Bonnefoi, 2017, npj Breast Cancer.

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

G. Thomas, D. Cox, H. Blanché, 2016, Breast Cancer Research.

Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.

S. Schraub, G. Calais, T. Delozier, 2001, European journal of cancer.

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers

G. Romieu, E. Crapez, P. Lamy, 2018, British Journal of Cancer.

New advances in DPYD genotype and risk of severe toxicity under capecitabine

F. Pinguet, C. Béroud, A. V. van Kuilenburg, 2017, PloS one.

[UPA/PAI-1: a tool for breast cancer treatment individualization. Biology, clinical implications and quantification assays].

G. Romieu, P. Lamy, W. Jacot, 2010, Bulletin du Cancer.

Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.

M. Buyse, M. Namer, F. Penault-Llorca, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the “APAD1” randomized controlled trial

I. Romieu, G. Romieu, G. Ninot, 2019, BMC Cancer.

Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: design and implementation of a prospective randomized controlled trial.

G. Romieu, G. Ninot, F. Cousson-Gélie, 2013, Contemporary clinical trials.

Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the “APAD1” randomized controlled trial

I. Romieu, G. Romieu, G. Ninot, 2019, BMC Cancer.

Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.

I. Bièche, G. MacGrogan, L. Mauriac, 2007, Anticancer research.

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.

M. Citron, M. Campone, L. Dirix, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study.

D. Miles, L. Mauriac, L. Dirix, 2009 .

Early drop of circulating tumor cells (CTC) and increase of circulating endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in multicenter phase II trial BEVERLY 1.

T. Delozier, F. André, J. Bonneterre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial

L. Mauriac, G. Romieu, J. Bines, 2009, Breast Cancer Research and Treatment.

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases

G. Romieu, V. D’Hondt, F. Dalenc, 2016, Breast Cancer Research and Treatment.

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

J. Machiels, T. Delozier, F. Penault-Llorca, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer

G. Romieu, V. D’Hondt, W. Jacot, 2021, BMC cancer.

Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification1)

G. Romieu, P. Lamy, W. Jacot, 2013, Clinical Chemistry and Laboratory Medicine.

Abstract P6-17-03: Trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer and brain metastases

G. Romieu, V. D’Hondt, F. Dalenc, 2016 .

TRIAL A phase I / II trial of the safety and clinical activity of a HER 2-protein based immunotherapeutic for treating women with HER 2-positive metastatic breast cancer

A. Callegaro, G. Curigliano, M. Campone, 2016 .

Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases

G. Romieu, W. Jacot, J. Ferrero, 2013, BMC Cancer.

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers

P. Colombo, G. Romieu, P. Lamy, 2015, BMC Cancer.

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients

G. Romieu, P. Lamy, W. Jacot, 2016, BMC Cancer.

[Hormone receptors and HER-2 changes during breast cancer progression: clinical implications].

G. Romieu, F. Bibeau, W. Jacot, 2011, Bulletin du Cancer.

Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumors.

S. Culine, F. Pinguet, M. Ychou, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer.

S. Culine, F. Pinguet, C. Astre, 2001, European journal of cancer.

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

M. Piccart, W. Gradishar, J. Robertson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

M. Espié, D. Khayat, G. Romieu, 2013, The Lancet. Oncology.

Comprehensive molecular characterization of mitochondrial genomes in human cancers

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2017, bioRxiv.

Author Correction: Pan-cancer analysis of whole genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2023, Nature.

G. Romieu, G. Ninot, C. Bortolon, 2014, Psycho-oncology.

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.

V. Valero, T. Wilson, M. Campone, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis and predictive values for clinical utility in breast cancer management

G. Romieu, C. Mazouni, J. Bonastre, 2014 .

Gemcitabine and docetaxel as front‐line chemotherapy in patients with carcinoma of an unknown primary site

S. Culine, F. Pinguet, M. Ychou, 2004, Cancer.

Sex differences in oncogenic mutational processes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2019, Nature Communications.

Safety analysis from PACS 04-A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients: Preliminary results.

T. Delozier, B. Asselain, J. Canon, 2006, Journal of Clinical Oncology.

Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.

M. Espié, D. Khayat, G. Romieu, 2015, European journal of cancer.

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients

G. Thomas, D. Cox, H. Blanché, 2016, Oncotarget.

Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients

R. Mirimanoff, G. Romieu, M. Ozsahin, 2004, British Journal of Cancer.

J. Lemonnier, G. Romieu, J. Pierga, 2020, Pharmaceuticals.

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

M. Espié, G. Romieu, I. Pauporté, 2018, Breast.

Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.

K. Zaman, G. Romieu, M. Ozsahin, 2010, The Lancet. Oncology.

HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort

P. Rouanet, G. Romieu, J. Daurès, 2014, Cancer medicine.

Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy

G. Romieu, P. Lamy, W. Jacot, 2012, Breast Cancer Research and Treatment.

Re: clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.

G. Romieu, P. Lamy, W. Jacot, 2013, Journal of the National Cancer Institute.

LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer

J. Abraham, H. Earl, H. Joensuu, 2021, Annals of Oncology.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Abstract P3-15-04: A French prospective pilot study to identify dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients receiving capecitabine

F. Pinguet, J. Bonneterre, G. Romieu, 2013 .

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

D. Cox, H. Bonnefoi, G. Romieu, 2017, European journal of cancer.

ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL

M. Espié, M. Dowsett, R. Gelber, 2012 .

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers

P. Colombo, G. Romieu, P. Lamy, 2015, BMC Cancer.

Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support

S. Culine, G. Romieu, S. Gourgou, 2004, Cancer.

Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer.

S. Culine, G. Romieu, J. Droz, 2013, Journal of geriatric oncology.

[Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].

G. Romieu, M. Ozsahin, C. Lemanski, 2004, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.

M. Espié, D. Khayat, G. Romieu, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

G. Thomas, D. Cox, H. Blanché, 2017, npj Breast Cancer.

Abstract P3-06-08: Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)

M. Oestergaard, F. Puglisi, G. Romieu, 2015 .

Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site

S. Culine, F. Pinguet, M. Ychou, 2002, Cancer.

Multicenter, non-randomized phase II study with RPR109881 in taxane-exposed metastatic breast cancer (MBC) patients (pts): Final results

G. Romieu, V. Diéras, P. Kaufman, 2005 .

Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label study

H. Bonnefoi, G. Romieu, P. Viens, 2008 .

P1-06-12: Circulating Tumor Cells (CTC) Monitoring during Phase II Study with Lapatinib (L) and Capecitabine (C) in Patients with Brain Metastases from HER2−Positive (+) Metastatic Breast Cancer (MBC) before Whole Brain Radiotherapy (WBR): LANDSCAPE Study.

M. Campone, G. Romieu, F. Bidard, 2011 .

A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Nuno A. Fonseca, Benjamin J. Raphael, Allison P. Heath, 2020, Nature Communications.

Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.

A. Goldhirsch, G. Curigliano, G. Romieu, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).

N. Harbeck, D. Miles, L. Dirix, 2009 .

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences

E. Birney, M. Ringnér, A. Børresen-Dale, 2019, Nature.

ASTER 70s UNICANCER phase III Trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?

O. Mir, M. Lacroix-Triki, E. Blot, 2014 .

[uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].

J. Peyrat, G. Romieu, P. Lamy, 2014, Annales de pathologie.

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

M. Parmar, J. Mackey, D. Cameron, 2013, The Lancet. Oncology.

1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)

D. Miles, L. Dirix, J. Cortes, 2011 .

PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy

G. Romieu, P. Lamy, F. Dalenc, 2019, Breast Cancer Research and Treatment.

[Physical activity and cancer survival].

B. Fervers, I. Romieu, G. Romieu, 2012, Bulletin du Cancer.

Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences

E. Birney, M. Ringnér, A. Børresen-Dale, 2019, Nature.

353OEFFICACY AND SAFETY IN TANIA, A RANDOMISED PHASE III TRIAL OF CONTINUED OR REINTRODUCED BEVACIZUMAB (BEV) AFTER 1ST-LINE BEV FOR HER2-NEGATIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC).

F. Puglisi, G. Romieu, G. von Minckwitz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.